Risperdal Maker Johnson & Johnson to Pay $2.2 Billion in Settlement

Posted By The Carlson Law Firm || 6-Nov-2013

After promotion safety advocates are calling irresponsible and improper, drug maker giant, Johnson & Johnson is facing more than $2.2 Billion in settlement fines brought on both criminally and civilly as a result of promotions for Risperdal, the New York Times reported yesterday.

The settlement fines come alongside accusations that the drug maker improperly promoted Risperdal to children and elderly for problems and conditions that were not previously approved by the Food and Drug Administration (FDA).

The anti-psychotic drug, Risperdal, which was previously one of Johnson & Johnson’s best selling drug, was not approved for developmental conditions and issues in children, nor elderly patients. In addition to improper marketing tactics pushing the Risperdal among vulnerable patients the drug was not approved for, the lawsuit against Johnson & Johnson also highlighted kickbacks the company reportedly paid to pharmacists and doctors, who in turn, reportedly, pushed the drug.

Risperdal & Elderly Patients

Risperdal, also known as risperdone, was approved in 1993, for use among schizophrenia patients. Johnson & Johnson later sought approval for the drug to be used among elderly dementia patients but the FDA did not agree with Risperdal for dementia in older patients and denied approval. Despite disapproval, the lawsuit against Johnson & Johnson charged that the drug giant continued to actively market to the elderly and health care professionals serving that demographic, hiring a sales force specifically targeting older Americans. While Risperdal was marketed as a method of calming agitated elderly patients in nursing home and other settings, the drug was also, knowingly, tied to increased risks of stroke, a side effects that can be potentially fatal among elderly populations with already higher risk factors.

Boys & Risperdal Breast Growth

Approval for use among children was not received by Johnson & Johnson from the FDA until 2006. But despite late approval of the Risperdal in children, the drug maker was similarly accused of marketing the anti-psychotic to child psychologists and child-based mental health facilities. Risperdal was pushed as a treatment for conditions and problems, such as ADHD and OCD among children despite some the serious side effects the drug was linked to. Breast development among boys using Risperdal is just one of the side effects cropping up among children, the Food and Drug Administration noted.

Although consumers trust their doctors and health care professionals with decisions and suggestions regarding their health and the health of their children and family members, the $2.2 Billion settlement required of Johnson & Johnson highlights the power of drug companies in the health and wellness of patients. Despite risks and lacking approval, the drug maker displayed carelessness and irreverence for patients by marketing to them and their doctors anyway, disregarding the Food and Drug Administration and overlooking associated risks.

Risperdal Attorneys: Help for Injured Patients

If you’ve been endured serious Risperdal side effects or have a boy developing breasts from Risperdal use, call our Risperdal attorneys for a free consultation today. Our team of defective drug attorneys are currently representing clients suffering the ill side effects of Risperdal. We care. We can help.


Other Blogs

Back to Top